The use of existing guidelines for pediatric treatment varies significantly among sites, a new study has found. The study findingssuggest wide variation exists in the medications prescribed to treat ...

A recent study posted to medRxiv* preprint server reported a novel form of post-acute coronavirus disease 2019 (COVID-19) syndrome in children. Study: Acute tubulointerstitial nephritis with or ...

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

A new study found that people who were diagnosed with lupus nephritis (LN) during childhood tend to have abnormal short-term kidney outcomes, especially if they are male and were diagnosed at an older ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

Roche has received approval from the European Commission (EC) for its humanised monoclonal antibody Gazyva/Gazyvaro ...

Basel: Roche has announced that the European Commission has approved Gazyva/Gazyvaro (obinutuzumab) in combination with ...

The US Food and Drug Administration (FDA) has approved belimumab (Benlysta) for treating active lupus nephritis (LN) in children aged 5–17 years. The drug can now be used to treat adult and pediatric ...

Gazyva/Gazyvaro is approved for adults with lupus nephritis in the United States and European Union and in over 100 countries for various types of haematological cancers.